Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd)
NCT01857115 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 63
Last updated 2024-11-13
Summary
This protocol is a phase I/II multicenter study designed to assess the safety and the efficacy of the proposed combinations as up-front treatment in elderly Multiple Myeloma (MM) patients.
Conditions
Interventions
- DRUG
- DRUG
- DRUG
Sponsors & Collaborators
-
Fondazione EMN Italy Onlus
collaborator OTHER -
European Myeloma Network B.V.
lead NETWORK
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 65 Years
- Max Age
- 99 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-04-30
- Primary Completion
- 2013-11-30
- Completion
- 2024-09-01
Countries
- Italy
Study Locations
More Related Trials
-
Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma
NCT01057225 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.
NCT02203643 ·Status: COMPLETED ·Phase: PHASE2
-
Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM
NCT05909826 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM)
NCT02206503 ·Status: COMPLETED ·Phase: PHASE2
-
High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma
NCT02597062 ·Status: COMPLETED ·Phase: PHASE2
-
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
NCT01980589 ·Status: COMPLETED ·Phase: PHASE1
-
Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects
NCT01091831 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple Myeloma
NCT00813150 ·Status: COMPLETED ·Phase: PHASE3
-
Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM
NCT03673826 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Carfilzomib, Cyclophosphamide, Dexamethasone in Transplant Eligible Newly Diagnosed High-risk Multiple Myeloma
NCT02217163 ·Status: COMPLETED ·Phase: PHASE2
-
A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma
NCT01660750 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet
NCT04191616 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers
NCT03512353 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
NCT07284758 ·Status: RECRUITING ·Phase: PHASE2
-
Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma
NCT01549431 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma
NCT02951819 ·Status: COMPLETED ·Phase: PHASE2
-
Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)
NCT00750815 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
NCT01816971 ·Status: COMPLETED ·Phase: PHASE2
-
Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma
NCT04287855 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
NCT02412878 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Of Daratumumab, Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without Pomalidomide
NCT03215524 ·Status: COMPLETED ·Phase: PHASE2
-
Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma (MM) Relapsed and/or Refractory to Lenalidomide
NCT01166113 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Phase II Multicenter, Open-label, Single Arm Clinical Study of Pomalidomide and dexamethasonE and Cyclophosphamide
NCT02046915 ·Status: COMPLETED ·Phase: PHASE2
-
Carfilzomib/Cyclophosphamide/Dexamethasone with Maintenance Carfilzomib in Multiple Myeloma
NCT02315716 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
NCT00424047 ·Status: COMPLETED ·Phase: PHASE3